Skip to main content

Mortality in Rheumatic Heart Disease Is High

Medically reviewed by Carmen Pope, BPharm. Last updated on June 7, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, June 7, 2024 -- Mortality related to rheumatic heart disease (RHD) is high and is correlated with the severity of valve disease, according to a study published online June 5 in the Journal of the American Medical Association.

Ganesan Karthikeyan, D.M., from the All India Institute of Medical Sciences in New Delhi, and colleagues assessed the risk and predictors of major patient-important clinical outcomes in patients with clinical RHD. Analysis included 13,696 patients in 24 low- and middle-income countries.

The researchers found that over a median duration of 3.2 years, 15 percent of patients died overall (4.7 percent per patient-year). Vascular causes accounted for most deaths (67.5 percent), mainly heart failure or sudden cardiac death. Both stroke (0.6 percent per year) and recurrent rheumatic fever was rare. Higher mortality was seen with markers of severe valve disease, including congestive heart failure (hazard ratio [HR], 1.58), pulmonary hypertension (HR, 1.52), and atrial fibrillation (HR, 1.30). Lower mortality was seen with surgical treatment (HR, 0.23) or valvuloplasty (HR, 0.24). Lower mortality was also seen with higher country income level, when adjusting for patient-level factors.

"Study findings suggest a greater need to improve access to surgical and interventional care, in addition to the current approaches focused on antibiotic prophylaxis and anticoagulation," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Bayer, which funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Rare Predicted Loss-of-Function Variants, Polygenic Risk Score Linked to Risk of A-Fib

THURSDAY, June 27, 2024 -- Rare predicted loss-of-function (pLOF) variants and a polygenic risk score (PRS) are associated with increased atrial fibrillation (AF) risk, according...

Lower Risk of ALS Seen for Men With High Levels of Physical Activity, Fitness

WEDNESDAY, June 26, 2024 -- For men, high levels of physical activity and fitness are associated with reduced risk of amyotrophic lateral sclerosis (ALS), according to a study...

Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma

WEDNESDAY, June 26, 2024 -- Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.